Nura Health

What Nura Health does

Nura Health is a privately held, boutique diagnostics and precision medicine company founded in 2024 and headquartered in Irvine, California, focused on women's reproductive health. The company's flagship offering is a patent-pending, non-invasive blood test for endometriosis and infertility risk, supported by a patient-facing platform (EMMA) that allows consumers to order the test, schedule services, and access results from home. The target population spans three personas: young women (14-25) with chronic pelvic pain, infertile women (30-45) pursuing fertility workups, and women with a confirmed endometriosis diagnosis (17-49) seeking recurrence monitoring.

The diagnostic uses a proprietary multi-modal biomarker signature analyzed through AI and machine learning algorithms to deliver a diagnostic probability of up to 90% versus surgical standards, paired with patient subtyping intended to guide treatment selection. The test is processed through IHDLab, an FDA and CLIA-accredited commercial laboratory partner, which the company states enables test availability at 80%+ of women's health clinics on the West Coast. The scientific foundation draws on 25+ years of women's health research led by co-founder and CSO Idhaliz Flores (PhD, 60+ peer-reviewed publications).

Nura Health's commercial model is hybrid: a direct-to-consumer B2C platform anchors the consumer journey from home to result, layered with channel partnerships across fertility clinics, OB/GYN practices, and telehealth platforms across the United States, plus value-based contracting outreach to Medicaid, Medi-Cal, employer health networks, and global payers. Revenue is generated through one-time diagnostic testing fees, although pricing is not publicly disclosed. The company has secured a $3 million ARPA-H grant under the Sprint for Women's Health initiative (2024) and a board-approved strategic research partnership with Sur180 Therapeutics (March 2026) to integrate its diagnostics pipeline with non-hormonal endometriosis therapeutics.

Name

Nura Health

Legal name

Nura Health

Website

https://getnura.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Nura Health is a boutique precision medicine company that has developed a patent-pending, AI-driven non-invasive blood test for endometriosis diagnosis, targeting women with chronic pelvic pain, unexplained infertility, and confirmed endometriosis across the United States.

Ownership category

akta.pro rank

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Diagnostic Testing Services: Revenue generated from the sale of non-invasive endometriosis blood tests to consumers and healthcare providers. The test is ordered through a B2C platform and processed through CLIA-accredited laboratory partnerships.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Nura Health develops and commercializes a patent-pending, non-invasive AI-driven blood test that diagnoses endometriosis and assesses infertility risk, reducing time-to-diagnosis from 8–12 years to 3–5 days and achieving up to 90% probability of diagnosis equivalent to surgical standards. The offering is built on a multi-modal biomarker signature combined with machine learning and patient subtyping to guide personalized treatment selection. The company also provides a patient-facing platform (EMMA) for scheduling tests, accessing results, and managing the endometriosis care journey.

Product overview

Nura Health is a boutique diagnostics and precision medicine company offering a single core product: a non-invasive blood test for endometriosis diagnosis. The test leverages AI and machine learning with multi-modal biomarker signatures to provide rapid diagnosis (3-5 days vs. 8-12 years traditionally). The company also provides a patient portal (EMMA) for consumers to access testing and results, and offers personalized treatment recommendations through predictive analytics, pharmacogenetics, and real-world data integration. The portfolio is focused on women's reproductive health, specifically endometriosis and fertility risk assessment.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-Invasive Endometriosis Blood Test

Quantifiable outcome

• Reduces diagnosis time from 8-12 years to 3-5 days
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Sur180 TherapeuticscoreStrategic or Co-development Partner · 24 March 2026Strategic research partnership approved by both companies' boards to integrate precision diagnostics with non-hormonal therapeutics for endometriosis. Combines Nura Health's multi-modal biomarker signature and patient subtyping capabilities with Sur180's novel non-hormonal therapeutic development targeting the stress-response pathway. The collaboration coordinates research workflows, data-sharing, biomarker analytics, and clinical activities to improve diagnostic accuracy and guide treatment selection.
• IHDLabcoreStrategic or Co-development PartnerFDA & CLIA-accredited commercial laboratory partnership enabling Nura Health to rapidly scale test availability to 80%+ of women's health clinics on the West Coast. Provides the laboratory infrastructure for processing endometriosis diagnostic tests.
• Fertility Clinics, OB/GYN Practices, and Telehealth PlatformscoreChannel Partner/ Reseller/ DistributorClinical collaborations with world-renowned institutions and experts in reproductive endocrinology, minimally invasive gynecology, and precision medicine. Partnerships across the United States to accelerate go-to-market strategy for the endometriosis diagnostic test.

Scale indicators9 records

Recent moves4 records

Expansion highlights6 records

Direct peers

• DotLab: DotLab is a women's health diagnostics company that has developed a blood-based biomarker test for endometriosis (the dotEndo test). It is the most direct competitor to Nura Health, targeting the same patient segments and clinical use case.
• Hera Biotech: Hera Biotech is a women's health company developing non-invasive molecular diagnostics for endometriosis using tissue-based and blood-based approaches. It targets the same patient population with a similar diagnostic proposition to Nura Health.
• Aspira Women's Health: Aspira Women's Health develops blood-based and protein-based diagnostic tests for ovarian cancer and other gynecological conditions, serving similar OB/GYN and women's health provider channels as Nura Health.
• Progenity: Progenity is a molecular and genetics diagnostics company with offerings in reproductive health, prenatal testing, and women's health. It serves similar clinical channels and patient populations as Nura Health.

Emerging players

• NextGen Jane: NextGen Jane is an early-stage reproductive health diagnostics company analyzing menstrual blood for endometriosis, fertility, and other gynecological conditions. It overlaps with Nura Health on endometriosis detection using novel sample types and biomarker analytics.
• Modern Fertility (Ro): Modern Fertility, now part of Ro, sells consumer-facing hormone and fertility blood tests directly to women. It overlaps with Nura Health on the B2C women's reproductive health testing category and shares target demographics.

Broad incumbents

• Myriad Genetics: Myriad Genetics is an established molecular diagnostics company offering genetic and biomarker tests across oncology, women's health, and reproductive conditions. It is a broader incumbent that could enter or expand in the endometriosis testing category.
• Exact Sciences: Exact Sciences is a leading molecular diagnostics company with a broad portfolio including Cologuard and Oncotype tests. Its scale and laboratory infrastructure make it a relevant incumbent competitor if it expands into women's reproductive health diagnostics.
• Invitae: Invitae is a large genetic testing and diagnostics company offering hereditary cancer, reproductive health, and proactive screening tests. It is a broad incumbent with overlapping capabilities in women's health biomarker and genetic testing.
• CooperSurgical: CooperSurgical is a major women's health medical device and diagnostics company serving OB/GYNs, fertility clinics, and reproductive endocrinologists globally. It is a broad incumbent distributor and product developer in the same clinical channels as Nura Health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nura-health-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nura Health